BiotechTV's banner

BiotechTV

@BiotechTV • 11,598 subscribers

Daily biotech news, content, and exclusive interviews.

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video:

𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video:

10,996,439 просмотров • 2 месяцев назад

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

36,428 просмотров • 1 месяц назад

𝐄𝐩𝐢𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐬: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.

𝐄𝐩𝐢𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐬: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.

85,155 просмотров • 5 месяцев назад

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

22,305 просмотров • 1 месяц назад

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Meeting spaces around Union Square are so expensive during JPM that one venture capital firm decided to host its meetings this week on a van roving around town. Say hello to THE HATTEBUS.

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Meeting spaces around Union Square are so expensive during JPM that one venture capital firm decided to host its meetings this week on a van roving around town. Say hello to THE HATTEBUS.

98,187 просмотров • 6 месяцев назад

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!

20,583 просмотров • 1 месяц назад

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:

73,893 просмотров • 6 месяцев назад

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:

16,768 просмотров • 1 месяц назад

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:

68,717 просмотров • 11 месяцев назад

𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: An early investor in recent mega successes such as Revolution Medicines, Peloton, Blueprint Medicines, and Parabilis, Thilo Schroeder describes his investment philosophy and focus on precision oncology. Full video:

𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: An early investor in recent mega successes such as Revolution Medicines, Peloton, Blueprint Medicines, and Parabilis, Thilo Schroeder describes his investment philosophy and focus on precision oncology. Full video:

13,446 просмотров • 1 месяц назад

𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video:

𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video:

29,397 просмотров • 5 месяцев назад

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐌&𝐀 𝐍𝐞𝐰𝐬: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐌&𝐀 𝐍𝐞𝐰𝐬: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.

20,285 просмотров • 3 месяцев назад

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: John Maraganore 🇺🇸🇬🇷🇺🇦 has been a champion of innovation throughout his career. He and Matt Gline discuss the road to success at Alnylam Pharmaceuticals, today's environment, and keeping the U.S. on top. Watch the episode:

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: John Maraganore 🇺🇸🇬🇷🇺🇦 has been a champion of innovation throughout his career. He and Matt Gline discuss the road to success at Alnylam Pharmaceuticals, today's environment, and keeping the U.S. on top. Watch the episode:

18,386 просмотров • 3 месяцев назад

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:

11,479 просмотров • 2 месяцев назад

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:

24,695 просмотров • 6 месяцев назад

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:

25,829 просмотров • 6 месяцев назад

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:

37,174 просмотров • 1 год назад

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:

42,139 просмотров • 1 год назад

𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: KeloniaTx presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation. Full video:

𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: KeloniaTx presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation. Full video:

21,941 просмотров • 7 месяцев назад

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes. $SANA Full video:

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes. $SANA Full video:

19,210 просмотров • 6 месяцев назад